Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.

You may also be interested in...

Angiomax Generics Imminent After Court Rules Patents Are Invalid

Exactly when The Medicine Co.'s top seller will see competition isn't clear – highlighting industry concerns with FDA review times for ANDAs. Hospira and Sagent have tentative approval and several other firms have pending applications.

The Medicines Co. Sets The (Commercial) Stage For New Launches

CEO Clive Meanwell detailed plans to deploy a 400-person commercial group in the U.S. to target 1,100 leading hospitals in the U.S.

Angiomax Patent Decision, Seven Possible Approvals Mean Catalytic Year For The Medicines Co.

While readying an appeal to a patent ruling benefiting Hospira’s efforts to introduce an Angiomax generic, the hospital-care specialist has several drugs nearing regulatory decisions in the U.S. and Europe.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts